CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
47.49
+0.79 (1.69%)
At close: Jun 27, 2025, 4:00 PM
47.00
-0.49 (-1.03%)
After-hours: Jun 27, 2025, 7:56 PM EDT
CRISPR Therapeutics AG Revenue
CRISPR Therapeutics AG had revenue of $865.00K in the quarter ending March 31, 2025, with 71.63% growth. This brings the company's revenue in the last twelve months to $37.68M, down -86.13% year-over-year. In the year 2024, CRISPR Therapeutics AG had annual revenue of $37.31M, down -89.95%.
Revenue (ttm)
$37.68M
Revenue Growth
-86.13%
P/S Ratio
100.71
Revenue / Employee
$95,865
Employees
393
Market Cap
4.36B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 37.31M | -333.89M | -89.95% |
Dec 31, 2023 | 371.21M | 370.01M | 30,885.48% |
Dec 31, 2022 | 1.20M | -913.77M | -99.87% |
Dec 31, 2021 | 914.96M | 914.24M | 127,154.94% |
Dec 31, 2020 | 719.00K | -288.87M | -99.75% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CRSP News
- 2 days ago - CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline - GlobeNewsWire
- 14 days ago - Crispr Therapeutics: Betting On A One-Shot Future - Seeking Alpha
- 18 days ago - CRISPR Therapeutics AG (CRSP) Goldman Sachs 46th Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 24 days ago - CRISPR Therapeutics AG (CRSP) William Blair's 45th Annual Growth Stock Conference (Transcript) - Seeking Alpha
- 4 weeks ago - CRISPR Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines - Seeking Alpha
- 7 weeks ago - CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade) - Seeking Alpha
- 7 weeks ago - Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course - Seeking Alpha